Ownership and insider activity for NeuroSense Therapeutics Ltd. (NRSN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).
Price
| Price | $6.49 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | IL |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $895000 | $699000 | $11.1M | $3.5M | $2.6M | $3.4M | $166000 |
| Short-term Investments | 0 | 0 | 0 | $3.5M | 0 | 0 | 0 |
| Receivables | $18000 | $30000 | $178000 | $131000 | $166000 | $164000 | $33000 |
| Inventory | -$18 | -$67 | -$178000 | 0 | 0 | 0 | 0 |
| Total Current Assets | $913000 | $729000 | $11.4M | $7.4M | $2.9M | $4.4M | $778000 |
| Property, Plant & Equipment | $7000 | $13000 | $19000 | $306000 | $247000 | $150000 | $228000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $955000 | $779000 | $11.4M | $7.7M | $3.2M | $4.6M | $1.0M |
| Accounts Payable | $23000 | $55000 | $39000 | $498000 | $1.5M | $1.2M | $799000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $37000 | $120000 | $597000 | $1.7M | $3.5M | $2.0M | $2.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $37000 | $120000 | $2.4M | $2.1M | $4.9M | $2.0M | $2.6M |
| Retained Earnings | -$1.6M | -$4.4M | -$8.4M | -$20.8M | -$26.1M | -$36.7M | -$47.8M |
| Total Equity | $918000 | $659000 | $9.0M | $5.6M | -$1.8M | $2.6M | -$1.6M |
| Total Debt | 0 | 0 | 0 | $211000 | $142000 | $73000 | $170000 |
| Net Debt | -$895000 | -$699000 | -$11.1M | -$6.9M | -$2.5M | -$3.3M | $4000 |
| Working Capital | $876000 | $609000 | $10.8M | $5.7M | -$543000 | $2.4M | -$1.7M |
Financial Health
| Debt / Equity | -0.11 |
| Current Ratio | 0.31 |
Profitability
| Return on Equity | 1070.23% |
| Return on Invested Capital | 797.48% |
| Return on Assets | -1082.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · CVKD · ENLV · KLTO · NERV · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NRSN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks